Validation of child-adapted short scales for measuring gastrointestinal-specific avoidance and anxiety

Maria Lalouni1,2,3 | Ola Olén1,4 | Johan Bjureberg2,5 | Marianne Bonnert2,5,6 | Trudie Chalder7 | Erik Hedman-Lagerlöf3 | Silje Endresen Reme8 | Eva Serlachius2,5 | Brjánn Ljótsson3,5

1Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
2Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden
3Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
4Department of Paediatric Gastroenterology and Nutrition, Sachs’ Children’s Hospital, Stockholm, Sweden
5Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden
6Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
7Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
8Department of Psychology, University of Oslo, Oslo, Norway

Abstract

Aim: To validate child-adapted shortened versions of the Irritable Bowel Syndrome-Behavioural Responses Questionnaire (IBS-BRQ; short scale denoted BRQ-C) and the Visceral Sensitivity Index (VSI; short scale denoted VSI-C) for children with functional abdominal pain disorders (FAPDs).

Methods: A child psychologist supervised by a child gastroenterologist was responsible for shortening the scales (BRQ-C, 11 items; and VSI-C, 7 items). Then, a sample of 89 children aged 8–12 years with FAPDs was used in the validation. Construct validity was assessed with correlations. Measures included gastrointestinal symptoms, quality of life, pain intensity and anxiety. Also, internal consistency, test–retest reliability, administration time and factor structure were assessed.

Results: Internal consistency for the BRQ-C and the VSI-C was α = 0.84 and α = 0.80, respectively. Correlations with related scales were similar between child-adapted scales and original scales, indicating construct validity equivalence. Correlations between short scales and original scales were high. Mean administration time was reduced by 47% (BRQ-C) and 42% (VSI-C), compared with original scales. Test–retest reliability was r = 0.72 for BRQ-C and r = 0.83 for VSI-C. BRQ-C had two factors (Avoidance and Bowel control). VSI-C had a unifactorial structure.

Abbreviations: BRQ-C, Behavioural responses questionnaire—child-adapted short scale; CBT, cognitive behavioural therapy; FACES, The Faces Pain Scale Revised; FAPoS, functional abdominal pain disorders; GI-anxiety, gastrointestinal-specific anxiety; GI-avoidance, gastrointestinal-specific avoidance; IBS, irritable bowel syndrome; IBS-BRQ, Irritable Bowel Syndrome-Behavioural Responses Questionnaire; PedsQL Gastro, The Paediatric Quality of Life Inventory Gastrointestinal Symptom Scale; PedsQL QOL, Paediatric Quality of Life Inventory; SCAS-S, Spence Children Anxiety Scale Short version; VSI, Visceral Sensitivity Index; VSI-C, The Visceral Sensitivity Index—Child-adapted short scale.
1 | INTRODUCTION

Paediatric functional abdominal pain disorders (FAPDs) are highly prevalent\(^1\) and include irritable bowel syndrome (IBS), functional dyspepsia and functional abdominal pain – not otherwise specified.\(^2\) Gastrointestinal-specific anxiety (GI-anxiety) is common in FAPDs and refers to anxiety about abdominal symptoms. GI-anxiety has been found to be a predictor of IBS in adults and to occur in individuals with IBS irrespective of anxiety disorders.\(^3\) GI-anxiety is often accompanied by gastrointestinal-specific avoidance (GI-avoidance), which refers to avoidance of situations and stimuli that might elicit abdominal symptoms (e.g., leisure activities, being in school and certain foods). While GI-avoidance can lead to short-term reduction of abdominal symptoms and GI-anxiety, it prevents the patient from gaining experience of being able to cope in the presence of these symptoms. This then maintains a vicious circle of GI-anxiety, GI-avoidance and symptom persistence.\(^4,5\) Reduced GI-anxiety and GI-avoidance have been shown to mediate symptom reduction in cognitive behavioural therapy (CBT) in adult, adolescent and paediatric FAPDs.\(^6–9\) Accordingly, GI-anxiety and GI-avoidance may be key mechanisms involved in the emergence and maintenance of paediatric FAPDs and constitute important treatment targets.

Despite the important role of GI-anxiety and GI-avoidance in FAPDs, there are no validated measures of GI-anxiety and GI-avoidance for children with FAPDs. In adults with IBS there are validated scales for both GI-anxiety; Visceral Sensitivity Index (VSI),\(^10\) and for GI-avoidance; Irritable Bowel Syndrome-Behavioural Responses Questionnaire (IBS-BRQ).\(^11\) The aim of this study was, therefore, to validate child-adapted versions of the VSI and the IBS-BRQ and to assess their reliability and factorial structure in children with FAPDs.

2 | METHODS

2.1 | Participants and inclusion

Data from a randomised controlled trial\(^12\) with 89 children (8–12 years old) with FAPDs (Sample 1) were used in the validation of the child-adapted short scales (ClinicalTrials.gov NCT02873078). Data from another treatment study (Sample 2), including 68 children and adolescents (ages 8–17 years) with FAPDs (ClinicalTrials.gov NCT03252743), were included in the factor analyses to increase statistical power (total \(N = 157\)). Children 8–12 years gave oral informed consent within the original studies, adolescents 13–17 years and parents gave written informed consent within the original studies. Physicians within primary, secondary or tertiary care referred participants into both samples and certified the children’s functional diagnoses. The studies were approved by the Regional Ethical Review Board in Stockholm (2016/1289-31; 2017/1342-31). Self-reports of the Rome IV criteria were used to differentiate between the subdiagnoses of FAPDs. Children were excluded if they had: (1) another somatic disorder that explained their symptoms, or (2) severe psychiatric or psychosocial problems in need of immediate care elsewhere.

2.2 | Measures

The Irritable Bowel Syndrome-Behavioural Responses Questionnaire (IBS-BRQ) is a 26 item scale for the assessment of controlling and avoidance behaviour related to IBS. The items are rated on a 7-point scale, between the endpoints: never and always. The IBS-BRQ has previously been shown to have high internal consistency (\(\alpha = 0.86\)) and high test-retest reliability (\(r = 0.81–0.85, p < 0.001\)) in a study with adult participants.\(^11\) In the original validation of the scale two factors, avoidance and control, were extracted using principal component analyses.

The Visceral Sensitivity Index (VSI) is a 15-item scale developed to assess GI-anxiety in IBS. In the VSI, the items are rated on a 6-point scale ranging from strongly disagree (1) to strongly agree (6). The scoring is then transformed to a 0–5 scale. The VSI has been found to have good psychometric properties with high internal consistency in different samples (\(\alpha = 0.90–0.93\))\(^10,13,14\) and ability to predict IBS symptom

---

**Conclusion:** The BRQ-C and the VSI-C were found to be time-saving, reliable and valid for children with FAPDs.

**Key notes**

- Gastrointestinal-specific anxiety and avoidance are common symptoms in children with paediatric functional abdominal pain disorders (FAPDs) and important treatment targets.
- Child-adapted short versions of the Irritable Bowel Syndrome-Behavioural Responses Questionnaire and Visceral Sensitivity Index were found to be reliable, valid and time-saving compared to the original scales.
- The short scales may be used to identify children with gastrointestinal-specific avoidance and anxiety and to repeatedly assess these symptoms during treatment.
severity. The studies were in adult participants. The VSI has been found to have a unifactorial structure in several studies.

The Behavioural Responses Questionnaire–Child-adapted short scale (BRQ-C) is an 11-item scale adapted from the IBS-BRQ within this study. The Visceral Sensitivity Index–Child-adapted short scale (VSI-C) is a 7-item scale adapted from the VSI, also within this study. The adaptation process is described in the section ‘Development of the scales’ in Appendix S1. The aims of the adaptation were to shorten the scales (to increase utility for screening, repeated assessments and use alongside other scales) and to increase the suitability for children with all FAPDs (as opposed to adults with IBS only), by changing wording when necessary and selecting the most relevant items for the target population. The first author (ML), a child psychologist with extensive experience of paediatric FAPDs and anxiety disorders was responsible for the adaptation of the scales under supervision of an experienced paediatric gastroenterologist (second author OO). The child-adapted short scales can be found in Appendix S2.

The Paediatric Quality of Life Inventory Gastrointestinal Symptom Scale (PedsQL Gastro) is a 9-item scale assessing the past month’s gastrointestinal symptoms. The scale has 5 points ranging from never to almost always. The PedsQL Gastro has been found to have acceptable reliability ($\alpha = 0.77$) for children with FAPDs and it has been shown to correlate with the measure of quality of life described below.  

Paediatric Quality of Life Inventory (PedsQL QOL) is a multidimensional 23-item scale assessing quality of life for children 8–12 years. The PedsQL QOL has high internal consistency ($\alpha = 0.88$). The scale has also been shown to differentiate between healthy and ill children and correlates with measures of illness, indicating high discriminative and concurrent validity, respectively.

The Faces Pain Scale Revised (FACES) assesses pain intensity. Hand-drawn human faces with pain expressions corresponding to numbers 0 (no pain), 2, 4, 6, 8 and 10 (worst pain) are used to help the child rate their worst pain during the past week. The FACES has shown strong correlations with ratings of pain intensity ($r = 0.92$) on a visual analogue scale in children with chronic pain.

Spence Children Anxiety Scale Short version (SCAS-S) is a 19-item scale that assesses anxiety in children 8–12 years. The frequency of symptoms such as ‘I am scared of the dark’ and ‘I worry about things’ are assessed on a 4-point scale with answers ranging from Never to Always. SCAS-S has demonstrated a high internal consistency ($\alpha = 0.88$).

### 2.3 Procedure

All assessments were self-administered via a secure online assessment platform.

Sample 1: The original IBS-BRQ and VSI scales and the adapted BRQ-C and VSI-C scales were assessed at screening or at pre-treatment assessment in a randomised order. That is, half of the children first completed the IBS-BRQ and VSI-C at screening and then later completed the BRQ-C and VSI at pre-treatment assessment, while the other half of the children completed the scales in reverse order. List randomiser at random.org was used to create a list for allocation to assessments at screening and pre-treatment. The other scales: PedsQL Gastro, PedsQL QOL, FACES and SCAS-S were assessed at the pre-treatment assessment. After the pre-treatment assessment, the children were randomised to internet-CBT or treatment as usual. The BRQ-C and VSI-C were then assessed with 14-day intervals. The first two assessments by the participants randomised to treatment as usual were used in test-retest reliability analyses ($n = 44$).

Sample 2: The children completed the BRQ-C and VSI-C at the pre-treatment assessment and these data were combined with Sample 1 in the exploratory factor analysis. All assessments are illustrated in Figure 1.

### 2.4 Statistical analyses

Statistical analyses were conducted in STATA version 13.1. Internal consistency for the BRQ-C, VSI-C, IBS-BRQ and VSI was examined by calculating Cronbach’s $\alpha$. Test-retest reliability for BRQ-C and VSI-C was calculated with Pearson’s product moment correlation $r$. Validity of BRQ-C and VSI-C were examined in two ways. First, the short versions were correlated with their respective long version using Pearson’s $r$. Second, the construct validity equivalence between the short and long scales was examined by

---

**FIGURE 1** Assessments included in sample 1 and sample 2. BRQ-C, Behavioural Responses Questionnaire–Child-adapted version; ICBT, Internet-delivered Cognitive Behavioural Therapy; IBS-BRQ, Irritable Bowel Syndrome–Behavioural Responses Questionnaire; TAU, Treatment As Usual; VSI-C, Visceral Sensitivity Index–Child-adapted version; VSI, Visceral Sensitivity Index
comparing the correlations between the short scales and the measures of gastrointestinal symptoms (PedsQL Gastro), quality of life (PedsQL QOL), pain intensity (FACES) and anxiety (SCAS-S) with the correlations between the long scales and the same measures. The average time to administer the original and the child-adapted versions of the scales were extracted from the online assessment platform. Assessment times >15 min for the BRQ-IBS and BRQ-C and >10 min for the VSI and VSI-C were removed to reduce the influence of outliers on the average assessment time. Because the original scales had been adapted to a new population (i.e. children with all FAPDs vs adults with IBS), exploratory factor analyses were used to identify latent constructs. Eigenvalues over 1 were retained according to the Kaiser criterion. Promax rotation, allowing factors to be correlated, was used to rotate the factors.

3 | RESULTS

3.1 | Baseline characteristics

Demographic characteristics of the participants, FAPDs diagnoses, means and standard deviations for all baseline measures included are presented in Table 1.

| TABLE 1 Demographics, FAPDs diagnoses and measures |
|-----------------------------------------------|
| Sample 1a (n = 89) | Sample 2b (n = 68) |
| **Demographics** | | |
| Age in years, mean (range) | 10.3 (8-12) | 12.3 (8-17) |
| Gender, n (%) female | 61 (69%) | 51 (74%) |
| Duration of abdominal symptoms, years, mean (SD) | 3.7 (2.1) | 4.6 (3.8) |
| **FAPDs diagnoses, n (%)** | | |
| IBS | 22 (25%) | 24 (35%) |
| FAP-NOS | 7 (8%) | 8 (12%) |
| IBS and FD | 22 (25%) | 15 (22%) |
| FD | 38 (43%) | 21 (31%) |
| **Measures, mean (SD)** | | |
| BRQ-C | 31.47 (12.7) | 26.8 (10.8) |
| IBS-BRQ | 30.6 (11.3) | |
| VSI-C | 14.24 (7.9) | 13.4 (8.5) |
| VSI | 20.7 (14.4) | |
| PedsQL Gastro | 57.8 (13.9) | |
| PedsQL QOL | 75.3 (13.2) | |
| FACES | 6.1 (2.3) | |
| SCAS-S | 12.9 (7.8) | |

Abbreviations: BRQ-C, Behavioural Responses Questionnaire–Child-adapted version; Faces, Faces Pain Rating Scale; FAP, Functional abdominal pain; FAPDs, Functional abdominal pain disorders; FAP-NOS, Functional abdominal pain—not otherwise specified; FD, Functional dyspepsia; IBS, Irritable bowel syndrome; IBS-BRQ, Irritable Bowel Syndrome–Behavioural Responses Questionnaire; PedsQL Gastro, Paediatric Quality of Life Inventory Gastrointestinal Symptom Scale; PedsQL QOL, Paediatric Quality of Life Inventory; SCAS-S, Spence Children Anxiety Scale Short version; SD, standard deviation; VSI, Visceral Sensitivity Index; VSI-C, Visceral Sensitivity Index–Child-adapted version.

3.2 | Reliability

The internal consistency for the BRQ-C was α = 0.84 and for the VSI-C α = 0.80. The internal consistency of the IBS-BRQ was α = 0.82 and for VSI it was α = 0.88. The 14-day test–retest reliability (n = 44) was r = 0.72 for BRQ-C and r = 0.83 for VSI-C.

3.3 | Validity

The correlation between the BRQ-C and the IBS-BRQ was r = 0.73, p < 0.001 and for the VSI-C and the VSI r = 0.70, p < 0.001. Correlations for the BRQ-C and the IBS-BRQ with the related measures administered were statistically significant and similar between the scales (Table 2). Likewise, the correlations for the VSI-C and the VSI with the related measures were statistically significant and similar between the scales (Table 3).

3.4 | Administration time

The mean time to administer the IBS-BRQ was 5:41 (minutes:seconds) and for the BRQ-C 3:00. For the VSI the mean administration time

---

Sample 1. Randomised controlled trial.

Sample 2. Treatment study with a pre-test post-test design. Data from Sample 2 was only used in the exploratory factor analyses (in combination with Sample 1).
was 3:30 and for the VSI-C 2:01. The administration time was reduced by 47% for the BRQ-C compared with the IBS-BRQ and 42% for the VSI-C compared with the VSI.

3.5 Exploratory factor analysis

In the exploratory factor analysis (Sample 1 and Sample 2 combined) two latent factors were found (eigenvalues 3.74 and 1.30, respectively) for BRQ-C. The items with strong loadings in factor 1 were all related to avoidance behaviours and this factor was labelled Avoidance. The Avoidance factor explained 70.5% of the variance in the model. The items with strong loadings in factor 2 all concerned bowel controlling behaviours and this factor was labelled Bowel control. This factor explained 51.5% of the variance in the model. The correlation between Avoidance and Bowel control was in the medium range (r = 0.42). VSI-C had a unifactorial structure (eigenvalue 3.05 for Factor 1). Factor 1 explained 93.7% of the variance in the model. The factor loadings for the items in the BRQ-C and the VSI-C are presented in Table 4.

4 DISCUSSION

The aim of the study was to validate the child-adapted short versions of the IBS-BRQ and the VSI, to be able to assess GI-avoidance and GI-anxiety in children with FAPDs. The child-adapted short scales, BRQ-C and VSI-C, showed high test-retest reliability and high internal consistency. Further, the child-adapted short scales showed equal construct validity, compared with the original scales. There was a reduction of administration time for the child-adapted short scales of 47% and 42%, which decreases the workload for children significantly. In the exploratory factor analysis we found two latent factors for BRQ-C: Avoidance and Safety behaviours. In the VSI-C we found a unifactorial structure.

The internal consistencies for the child-adapted short scales were slightly lower than for the original scales, which can be seen as a natural effect of decreasing the number of items. The correlations between the short and long scales were medium to high (r = 0.73 for the IBS-BRQ–BRQ-C and r = 0.70 for the VSI–VSI-C). Very high correlations were not expected since a main consideration in the selection of the items for the child-adapted short scales was that they should be relevant to children with different kinds of FAPDs and not only children with IBS.

In BRQ-C, the clear distribution of items into two behaviourally distinct latent factors: Avoidance (all items concern avoidance) and Bowel control (all items concern safety behaviours) supports the dimensionality found. The results also confirm the dimensionality found in the original validation of the IBS-BRQ. The latent factors were moderately correlated (r = 0.42), which may indicate that they represent different aspects of the same underlying construct.

The unidimensional structure found in VSI-C, confirms the factorial structure found in several other studies.

4.1 Limitations

The sample size for the validation of the child-adapted scales was 89 children with ages 8–12 years. This is a small sample size in this context and a rather narrow age range, which is a limitation to the study. In the exploratory factor analysis, the sample size was 157, which is also rather small. Also, because the child-adapted scales were developed from adult scales, some aspects in paediatric FAPDs may be missing. However, we have found the child-adapted scales to be feasible for children to administer and in our prior studies we found they were sensitive to change, and able to capture relevant change processes. A larger study with a broader age range that could confirm the reliability, validity and the factorial structure of the scales in the paediatric FAPD population is recommended for future research. We also suggest future studies might assess whether the BRQ-C and the VSI-C can differentiate between children with FAPDs and healthy controls.
4.2 | Clinical implications

BRQ-C and VSI-C may be used to identify children who have a high level of GI-avoidance and GI-anxiety. These children may respond particularly well to exposure-based CBT, considering that this treatment specifically targets behaviours and beliefs related to symptom-specific avoidance and anxiety. Changes in gastrointestinal-specific avoidance and anxiety have been shown to mediate symptom improvement in CBT. Therefore, it may be particularly useful to administer the BRQ-C and the VSI-C repeatedly to be able to follow patients’ trajectories of change during such treatment. Exacerbation of symptoms is not only present in functional abdominal disorders, but also in disorders with a clear pathology, such as inflammatory bowel disease (IBD) and celiac disease. A best practice update concludes that the psychological context is highly relevant for both FAPDs and disorders like IBD. The BRQ-C and the VSI-C could thus also be used to assess GI-avoidance and GI-anxiety in other disorders distinguished by abdominal pain.

5 | CONCLUSIONS

The current study presents the first evidence that the child-adapted short scales BRQ-C and the VSI-C are psychometrically reliable and valid measures of GI-avoidance and GI-anxiety in children with FAPDs. We conclude that the child-adapted short scales considerably lower the response burden for children compared with the original scales, particularly when repeated assessments are used.

AUTHOR CONTRIBUTIONS

ML, MB, JB, OO, ES, EHL, BL acquired the data. ML analysed and drafted the manuscript. All co-authors interpreted the data and critically revised the manuscript for important intellectual content.

ACKNOWLEDGEMENT

The authors would like to thank Professor Emeran Mayer, Dr Jennifer Labus and Professor Bruce Naliboff for the permission to adapt the Visceral Sensitivity Index for children with FAPDs and Dr Johan Åhlén for valuable input concerning the exploratory factor analysis.
CONFLICTS OF INTEREST
BL and EHL are shareholders of DahliaQomit AB, a company specialising in online psychiatric symptom assessment, and Hedman-Lagerlöf och Ljótsson psykologi AB, a company that licences cognitive behaviour therapy manuals. TC is part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Since this study was started, a private company has signed a licence agreement with King’s College London with a view to bringing the ReguL8 website product (cognitive behaviour therapy for irritable bowel syndrome) to the NHS and other international markets. TC will be a beneficiary of this licence through contracts with their respective universities. She has delivered workshops on persistent physical symptoms including bowel symptoms in the context of long-term conditions, during the conduct of the study for which she has received royalties. The remaining authors declare no conflicts of interest.

ORCID
Maria Lalouni https://orcid.org/0000-0002-6818-8156

REFERENCES
1. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One. 2015;10(5):e0126982.
2. Hyams JS, Lorenzo CD, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. Gastroenterology. 2016;150(6):1456-1468.
3. Hazlett-Stevens H, Craske MG, Mayer EA, Chang L, Naliboff BD. Prevalence of irritable bowel syndrome among university students. J Psychosom Res. 2003;55(6):501-505.
4. Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain. 2000;85(3):317-332.
5. Asmundson GJG, Noel M, Petter M, Parkerson HA. Pediatric fear-avoidance model of chronic pain: foundation, application and future directions. Pain Res Manag. 2012;17(6):397-405.
6. Ljótsson B, Hesser H, Andersson E, et al. Provoking symptoms to relieve symptoms: a randomized controlled dismantling study of exposure therapy in irritable bowel syndrome. Behav Res Ther. 2014;55:27-39.
7. Bonnert M, Olén O, Bjureberg J, et al. The role of avoidance behavior in the treatment of adolescents with irritable bowel syndrome: a mediation analysis. Behav Res Ther. 2018;105:27-35.
8. Hesser H, Hedman-Lagerlöf E, Andersson E, Lindfors P, Ljótsson B. How does exposure therapy work? A comparison between generic and gastrointestinal anxiety-spectrum mediators in a dismantling study of exposure therapy for irritable bowel syndrome. J Consult Clin Psychol. 2018;86(3):254-267.
9. Lalouni M, Hesser H, Bonnert M, et al. Breaking the vicious circle of fear and avoidance in children with abdominal pain: a mediation analysis. J Psychosom Res. 2021;140:110287.
10. Labus JS, Bolus R, Chang L, et al. The visceral sensitivity index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20(1):89-97.
11. Reme SE, Darnley S, Kennedy T, Chalder T. The development of the irritable bowel syndrome-behavioral responses questionnaire. J Psychosom Res. 2010;69(3):319-325.
12. Lalouni M, Ljótsson B, Bonnert M, et al. Clinical and cost effectiveness of online cognitive behavioral therapy in children with functional abdominal pain disorders. Clin Gastroenterol Hepatol. 2019;17(11):2236-2244.e11.
13. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med. 2007;69(1):89-98.
14. Saigo T, Tayama J, Hamaguchi T, et al. Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students. BioPsychoSocial Medicine. 2014;8(1):10.
15. Varni JW, Lane MM, Burwickle TM. Health-related quality of life in pediatric patients with irritable bowel syndrome: a comparative analysis. J Dev Behav Pediatr. 2006;27(6):451-458.
16. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800-812.
17. Hicks CL, Baeyer CL, von Spafford PA, Korlaar I, van Goodenough B. The faces pain scale-revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173-183.
18. Ahlen J, Vigerland S, Ghaderi A. Development of the Spence Children’s anxiety scale – short version (SCAS-S). Journal of Psychopathology and Behavioral Assessment. 2017;46(9):1-17.
19. Stata S. StataCorp. 2013 Stata Statistical Software: Release 13. StataCorp LP; 2013.
20. Fabrigar LR, Wegener DT, MacCallum RC, Strahan EJ. Evaluating the use of exploratory factor analysis in psychological research. Psychol Methods. 1999;4(3):272-299.
21. Braeken J, van Assen MALM. An empirical Kaiser criterion. Psychol Methods. 2017;22(3):450-466.
22. Acocck AC. Discovering Structural Equation Modeling Using Stata: Revised Edition. Stata Press; 2013.
23. Furr M. Scale Construction and Psychometrics for Social and Personality Psychology. SAGE Publications Ltd; 2011.
24. Bonnert M, Olén O, Lalouni M, et al. Internet-delivered cognitive behavior therapy for adolescents with irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2017;112(1):152-162.
25. Keefer L, Palsson OS, Pandolfini JE. Best practice update: incorporating psycho-gastroenterology into Management of Digestive Disorders. Gastroenterology. 2018;154(5):1249-1257.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lalouni M, Olén O, Bjureberg J, Bonnert M, Chalder T, Hedman-Lagerlöf E. Validation of child-adapted short scales for measuring gastrointestinal-specific avoidance and anxiety. Acta Paediatr. 2022;111:1621–1627. https://doi.org/10.1111/apa.16403